Trials / Completed
CompletedNCT02035605
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of ALN-AT3SC in healthy volunteers and Hemophilia A or B patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-AT3SC | Ascending doses of ALN-AT3SC by subcutaneous (sc) injection |
| DRUG | Sterile Normal Saline (0.9% NaCl) | Calculated volume to match active comparator |
Timeline
- Start date
- 2014-01-20
- Primary completion
- 2017-07-20
- Completion
- 2017-07-20
- First posted
- 2014-01-14
- Last updated
- 2020-12-19
Locations
14 sites across 5 countries: United States, Bulgaria, Russia, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02035605. Inclusion in this directory is not an endorsement.